Receipt date: 10/30/2017
`
`15/789,862 - GAU: 1674
`
`PTOISBI'DBa (03-15)
`Doc code' IDS
`Approved for use through 071312016. OMB 0651-0031
`.
`.
`.
`_
`'.
`.
`US. Patent and Trademark Office; US. DEPARTMENT OF COMMERCE
`Doc description. Information Disclosure Statement (IDS) Filed
`Under the Paperwork Reduction Act of 1995. no persons are required to respond to a collection of information unless it contains a valid OMB control number.
`
`
`
`| 5789862
`
`
`I N
`
`i'A
`
`Application Number
`Filing Date
`
`First Named Inventor
`
`
`
`
`IN FORMATION DISCLOSU RE
`
`STATEMENT BY APPLICANT
`
`( Not for submission under 37 CFR 1.99)
`
`Art Unit
`
`Examiner Name
`Not Yet Assigned
`Attorney Docket Number
`I AVN-OOQDVCNT
`
`
`
`
`
`
`
`
`U.S.PATENTS
`-
`
`
`Examiner Cite
`Initial*
`NO
`
`Patent Number
`
`Kind
`Code1 Issue Date
`
`Name of Patentee or Applicant
`Of cited Document
`
`Pages,ColumnS,LineS where
`Relevant Passages or Relevant
`Figures Appear
`
`
`
`If you wish to add additional US. Patent citation information please click the Add button.
`Add
`U.S.PATENT APPLICATION PUBLICATIONS -
`
`
`Examiner Cite No Publication
`Initial*
`Number
`
`Publication
`Kind
`Code1 Date
`
`Name of Patentee or Applicant
`Of cited Document
`
`Pages,ColumnS,LineS where
`Relevant Passages or Relevant
`Figures Appear
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`If you wish to add additional U.S. Published Application citation information please click the Add button. Add
`FOREIGN PATENT DOCUMENTS
`-
`
`
`
`Pages,Columns,LineS
`
`Name of Patentee or
`
`where Relevant
`Kind
`Publication
`
`Examiner Cite Foreign Document
`Applicant Of cited
`T5
`|nitia|*
`No
`Number3
`
`Code4 Date
`Passages or Relevant
`
`
`Document
`
`
`Figures Appear
`
`
`
`If you wish to add additional Foreign Patent Document citation information please click the Add button
`NON-PATENT LITERATURE DOCUMENTS -
`
`
`Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item
`T5
`(book, magazine, journal, serial, symposium, catalog, etc), date, pageS(S), volume-issue number(s),
`publisher, city and/or country where published.
`
`
`EFSWeb2.1.17
`
`ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH.
`
`/JPM/
`
`

`

`
`Receiptdajze; 10/10/2013
`15/789j52 —GAU: 1574
`
`Application Number
`15789862
`
`IN FORMATION DISCLOSU RE
`STATEMENT BY APPLICANT
`
`( Not for submission under 37 CFR 1.99)
`
`
`Filing Date
`2017-10-20
`First Named Inventor
`Peter SAZANI
`
`Art Unit
`|NIA
`
`
`
`Examiner Name
`Not Yet Assigned
`Attorney Docket Number
`|AVN-009DVCN7
`
`
`
`
`
`
`
`AKESHIMA, Yasuhiro et aI., "Modulation of In Vitro Splicing of the Upstream Intron by Modifying an lntra—Exon
`equence Which Is Deleted from the Dystrophin Gene in Dystrophin Kobe," J. Clin. Invest, Vol. 95:515-520 (1995)
`
`ANAKA, Kenji et al., "Polypurine Sequences within a Downstream Exon Function as a Splicing Enhancer," Molecular
`nd Cellular Biology, Vol. 14(2):1347—1354 (1994)
`
`elios Pharms., Inc. v. Merck KgaA, No. 96-1307, 1998 WL 35272018 (S.D. Cal. Nov. 18, 1998), 11 pages (Exhibit
`umber 2153 filed in interference 106013 on October 29, 2015)
`
`HANH, Le Thiet et aI., "Characterization of Revertant Muscle Fibers in Duchenne Muscular Dystrophy, Using Exon-
`pecific Monoclonal Antibodies against Dystrophin," Am. J. Hum. Genet, Vol. 56:725—731 (1995)
`
`he Regents of the University of California v. Dako North America, Inc., U.S.D.C., N.D. California, No. COS—03955
`HP, April 22, 2009 (2009 WL 1083446 (N.D.Cal.), Exhibit Number 1206 filed in Interferences 106,007 and 106,008
`n February 17, 2015.
`
`IAN, Xiaobing et aI., "Imaging Oncogene Expression," Ann. NY. Acad. Sci, Vol. 1002:165—188 (2003) (Exhibit
`umber 2029 filed in interferences 106008, 106013, 106007 on November 18, 2014)
`
`ranscript of 2nd Deposition of Erik J. Sontheimer, Ph.D., dated March 12, 2015, (Academisch Ziekenhuis Leiden
`xhibit 1231, filed April 3, 2015 in Interference 106007 and 106008, pages 1-185).
`
`ranscript of 2nd Deposition of Matthew J.A. Wood, M.D., D. Phil, dated March 5, 2015, (Academisch Ziekenhuis
`eiden Exhibit 1230, filed April 3, 2015 in Interference 106007 and 106008, pages 1—117).
`
`ranscript of December 12,2014 Teleconference with Administrative Patent Judge Schafer (rough draft) (previously
`fled in Int. No. 106,008 as Ex. 2114), Pages 28 Exhibit Number 1001 filed in Interference 106,013 on February 17,
`
`ranscript of the January 21, 2015 deposition of Erik Sontheimer, Ph.D., Patent Interference Nos. 106,007 and
`06,008, 98 pages, dated January 21, 2015 (Exhibit Number 2122 filed in interferences 106,007 and 106,008 on
`ebruary 17, 2015.
`
`ranscript of the March 11, 2015 deposition of Judith van Deutekom, Ph.D., (University of Western Australia Exhibit
`' 141, filed April 3, 2015 in lnterferences 106007, 106008, and 106013, pages 1—168).
`
`EFS Web 2.1.17
`
`ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH.
`
`/JPM/
`
`

`

`
`Receiptdajze; 10/10/2013
`15/789j52 —GAU: 1574
`
`Application Number
`15789862
`
`IN FORMATION DISCLOSU RE
`STATEMENT BY APPLICANT
`
`( Not for submission under 37 CFR 1.99)
`
`
`Filing Date
`2017-10-20
`First Named Inventor
`Peter SAZANI
`
`Art Unit
`|NIA
`
`
`
`Examiner Name
`Not Yet Assigned
`Attorney Docket Number
`|AVN-009DVCN7
`
`(A)N
`
`4:.
`
`—l—l"NlU'i
`
`
`
`
`
`
`
`—l—l
`
`—l
`
`ranscript of the March 12, 2015 deposition of Erik J. Sontheimer, Ph.D_, (University of Western Australia Exhibit 2142
`"ed April 3, 2015 in lnterferences 106007, 106008, and 106013, pages 1—183).
`
`ranscript of the March 5, 2015 deposition of Matthew J. A. Wood, M.D., D. PHIL., (University of Western Australia
`xhibit 2146, filed April 3, 2015 in Interferences 106007, 106008, and 106013, pages 1-115).
`
`ransfection of AON, Pages 1, Exhibit Number 1170 filed in Interferences 106,007 and 106,008 on February 16,
`
`.3. Food and Drug Administration Presentation at Peripheral and Central Nervous System Drugs Advisory
`ommittee, April 25, 2016, 178 pages.
`
`.3. Food and Drug Administration Statement, dated December 30, 2014 (2 pages), Exhibit Number 1204 filed in
`nterferences 106,007 and 106,008 on February 17, 2015.
`
`.3. Patent Application No. 12/198,007, as—filed August 25, 2008 ("the '007 Application") (Exhibit Number 1073 filed in
`nterferences 106008, 106007 on December 23,2014)
`
`.3. Patent Application No. 121976381, as—filed December 22, 2010 ("the '381 Application") (Exhibit Number 1074
`"ed in interferences 106008, 106007 on December 23, 2014)
`
`.3. Patent Application Publication No. 200110056077 ("Matsuo") 10 pages, (Exhibit Number 1080 filed in
`nterferences 106008, 106007 on December 23,2014)
`
`.3. Patent Application Publication No. 200210049173 ("Bennett et al.") 50 pages, (Exhibit Number 1081 filed in
`nterferences 106008, 106007 on December 23,2014)
`
`.3. Patent No. 5,190,931 ("the '931 Patent") 22 pages,(Exhibit Number 1069 filed in interferences 106008, 106007 on
`I ecember 23, 2014)
`
`.3. Patent No. 7,001,761 (the "Xiao" Patent) 64 pages, (Exhibit Number 1070 filed in interferences 106008, 106007
`n December 23, 2014)
`
`|\J|\J—‘O
`
`|\JN
`
`EFS Web 2.1.17
`
`ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH.
`
`/JPM/
`
`

`

`
`Receipt. date;
`ILL/WELT
`15/7&9,_8_62 — GAU: 1574
`
`15789862
`
`IN FORMATION DISCLOSU RE
`STATEMENT BY APPLICANT
`
`( Not for submission under 37 CFR 1.99)
`
`
`Filing Date
`2017-10-20
`First Named Inventor
`Peter SAZANI
`
`Art Unit
`|NIA
`
` Application Number
`
`
`
`Examiner Name
`Not Yet Assigned
`
`Attorney Docket Number |AVN-009DVCN7
`
`|\J00
`
`|\J4:.
`
`|\JUI
`
`00|\J|\J|\J|\JO(.0CO"-40')
`
`00 _.
`
`00N
`
`0000
`
`niversity of Western Australia Objections to Opposition Evidence, served on February 24, 2015 filed in Interference
`0. 106,007, Exhibit 2150, filed April 10, 2015 in Interference Nos. 106007 and 106008, pages 1-15.
`
`niversity of Western Australia Objections to Opposition Evidence, served on February 24, 2015, filed in Interference
`0. 106,008, Exhibit 2151, filed April 10, 2015, in Interference Nos. 106007and 106008, pages 1-15.
`
`niversity of Western Australia v. Academisch Ziekenhuis Leiden, Decision - Motions — 37 CFR. § 41 .125(a), filed in
`' atent Interference No. 106008, September 20, 2016, pages 1-20 (Doc 480)
`
`
`
`niversity of Western Australia v. Academisch Ziekenhuis Leiden, Decision - Motions — 37 CFR § 41 .125(a)
`Substitute), filed in Patent Interference No. 106007, May 12, 2016, pages 1-53 (Doc 476)
`
`niversity of Western Australia v. Academisch Ziekenhuis Leiden, Judgment - Motions — 37 CFR. § 41.127 filed in
`' atent Interference No. 106008, September 20, 2016, pages 1-3 (Doc 481)
`
`niversity of Western Australia v. Academisch Ziekenhuis Leiden, Judgment - Motions — 37 CFR § 41.127, filed in
`' atent Interference No. 106007, April 29, 2016, pages 1-3, (Doc 474)
`
`niversity of Western Australia v. Academisch Ziekenhuis Leiden, Redeclaration - 37 CFR 41 .203(c), filed in Patent
`nterference No. 106007, April 29, 2016, pages 1—2, (Doc 473)
`
`niversity of Western Australia v. Academisch Ziekenhuis Leiden, Withdrawal and Reissue of Decision on Motions,
`fled in Patent Interference No. 106007, May 12,2016, pages 1—2 (Doc 475)
`
`niversity of Western Australia v. Academisch Ziekenhuis Leiden, Academisch Ziekenhuis Leiden List of Exhibits (as
`f Apr. 3, 2015), filed in Patent Interference No. 106,007, April 3, 2015, pages 1—18, (Doc 423).
`
`niversity of Western Australia v. Academisch Ziekenhuis Leiden, Academisch Ziekenhuis Leiden List of Exhibits (as
`f Apr. 3, 2015), filed in Patent Interference No. 106,008, April 3, 2015, pages 1—1 8 (Doc 435).
`
`niversity of Western Australia v. Academisch Ziekenhuis Leiden, Academisch Ziekenhuis Leiden List of Exhibits, 18
`ages, Patent Interference No. 106,007, (Doc 391), dated February 17, 2015.
`
`EFSWeb2.1.17
`
`ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH.
`
`/JPM/
`
`
`
`

`

`
`Receipt. date;
`ILL/WELT
`15/7&9,_8_62 — GAU: 1574
`
`15789862
`
`IN FORMATION DISCLOSU RE
`STATEMENT BY APPLICANT
`
`( Not for submission under 37 CFR 1.99)
`
`
`Filing Date
`2017-10-20
`First Named Inventor
`Peter SAZANI
`
`Art Unit
`|NIA
`
` Application Number
`
`Examiner Name
`Not Yet Assigned
`
`Attorney Docket Number |AVN-009DVCN7
`
`
`
`004:.
`
`00UI
`
`000')
`
`4:-000000O(.003"-l
`
`4:. _.
`
`4:.N
`
`4:.00
`
`4:.4:.
`
`niversity of Western Australia v. Academisch Ziekenhuis Leiden, Academisch Ziekenhuis Leiden List of Exhibits, 18
`ages, Patent Interference No. 106,008, (Doc 398), dated February 17,2015.
`
`niversity of Western Australia v. Academisch Ziekenhuis Leiden, Academisch Ziekenhuis Leiden List of Exhibits, 3
`ages, Patent Interference No. 106,013, (Doc 147), dated February 17,2015.
`
`niversity of Western Australia v. Academisch Ziekenhuis Leiden, Academisch Ziekenhuis Leiden Notice of Service of
`upplemental Evidence, 3 pages, Patent Interference No. 106,007 (Doc 414), dated March 9, 2015.
`
`niversity of Western Australia v. Academisch Ziekenhuis Leiden, Academisch Ziekenhuis Leiden Notice of Service of
`upplemental Evidence, 3 pages, Patent Interference No. 106,008 (Doc 422), dated March 9, 2015.
`
`niversity of Western Australia v. Academisch Ziekenhuis Leiden, Academisch Ziekenhuis Leiden Opposition 1 (35 U.
`.C. § 112(3)), 83 pages, Patent Interference No. 106,008, (Doc 400), dated February 17, 2015
`
`niversity of Western Australia v. Academisch Ziekenhuis Leiden, Academisch Ziekenhuis Leiden Opposition 1 (35 U.
`.C. § 112(3)), 93 pages, Patent Interference No. 106,007, (Doc 392), dated February 17, 2015
`
`niversity of Western Australia v. Academisch Ziekenhuis Leiden, Academisch Ziekenhuis Leiden Opposition 1
`Standing Order 1) 203.1 and 37 CFR. § 41.202(a) and (e)), 20 pages, Patent Interference No. 106,013, (Doc 148),
`u ated February 17, 2015
`
`niversity of Western Australia v. Academisch Ziekenhuis Leiden, Academisch Ziekenhuis Leiden Opposition 2
`lndefiniteness), 31 pages, Patent Interference No. 106,007, (Doc 396), dated February 17, 2015
`
`
`
`niversity of Western Australia v. Academisch Ziekenhuis Leiden, Academisch Ziekenhuis Leiden Opposition 2
`lndefiniteness), 32 pages, Patent Interference No. 106,008, (Doc 401), dated February 17, 2015
`
`niversity of Western Australia v. Academisch Ziekenhuis Leiden, Academisch Ziekenhuis Leiden Opposition 3 (35 U.
`.C. §135(b)), 44 pages, Patent Interference No. 106,008, (Doc 397), dated February 17, 2015
`
`niversity of Western Australia v. Academisch Ziekenhuis Leiden, Academisch Ziekenhuis Leiden Opposition 3
`Standing Order § 203.1 and 37 CFR. § 41 .202(a) and (e)), 20 pages, Patent Interference No. 106,007, (Doc 389),
`ated February 17, 2015.
`
`EFSWeb2.1.17
`
`ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH.
`
`/JPM/
`
`
`
`

`

`
`Receipt date; 10/10/2013
`15/789L852 — GAU: 1574
`
`Application Number
`15789862
`
`
`
`IN FORMATION DISCLOSU RE
`STATEMENT BY APPLICANT
`
`( Not for submission under 37 CFR 1.99)
`
`
`Filing Date
`2017-10-20
`First Named Inventor
`Peter SAZANI
`
`Art Unit
`| MIA
`Examiner Name
`Not Yet Assigned
`Attorney Docket Number
`I AVN-OOQDVCNT
`
`
`
`
`
`niversity of Western Australia v. Academisch Ziekenhuis Leiden, Academisch Ziekenhuis Leiden Reply 1 (For
`udgment that UWA'a Claims are Unpatentable Under 35 U.S.C. §§ 102 and 103), dated April 3, 2015, filed in Patent
`nterference No. 106008, pages 1-17 (Doc 431).
`
`niversity of Western Australia v. Academisch Ziekenhuis Leiden, Academisch Ziekenhuis Leiden Reply 1 (For
`udgment that UWA's Claims are Unpatentable Under 35 U.S.C. §§ 102 and 103), dated April 3, 2015, filed in Patent
`nterference No. 106007, pages 1-17 (Doc 424).
`
`niversity of Western Australia v. Academisch Ziekenhuis Leiden, Academisch Ziekenhuis Leiden Reply 2 (To Deny
`he Benefit of AU 2004903474), dated April 3, 2015, filed in Patent Interference No. 106007, pages 1—11(Doc 425).
`
`Doc 433).
`
`niversity of Western Australia v. Academisch Ziekenhuis Leiden, Academisch Ziekenhuis Leiden Reply 2 (To Deny
`he Benefit of AU 2004903474), dated April 3, 2015, filed in Patent Interference No. 106008, pages 1—12 (Doc 432).
`
`niversity of Western Australia v. Academisch Ziekenhuis Leiden, Academisch Ziekenhuis Leiden Reply 3 (For
`udgment of Unpatentability based on Myriad) dated April 3, 2015, filed in Patent Interference No. 106007, pages 1-12
`Doc 426).
`
`niversity of Western Australia v. Academisch Ziekenhuis Leiden, Academisch Ziekenhuis Leiden Reply 3 (For
`udgment of Unpatentability based on Myriad) dated April 3, 2015, filed in Patent Interference No. 106008, pages 1-13
`
`If you wish to add additional non-patent literature document citation information please click the Add button Add
`EXAMINER SIGNATURE
`
`ExaminerSignature I
`
`/Jennifer Pitrak McDonald/
`
`Date Considered
`
`I 12/12/2017
`
`*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a
`citation if not in conformance and not considered.
`Include copy of this form with next communication to applicant.
`
`1 See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. 2 Enter office that issued the document, by the two-letter code (WIPO
`Standard ST.3). 3 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.
`4 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 5 Applicant is to place a check mark here if
`English language translation is attached.
`
`EFSWeb2.1.17
`
`ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH.
`
`/JPM/
`
`

`

`
`Receipt. date; 10/10/2013
`15/7&9,_8_62 — GAU: 1574
`
`15789862
`
`IN FORMATION DISCLOSU RE
`STATEMENT BY APPLICANT
`
`( Not for submission under 37 CFR 1.99)
`
`
`Filing Date
`2017-10-20
`First Named Inventor
`Peter SAZANI
`
`Art Unit
`|NIA
`
` Application Number
`
`Examiner Name
`Not Yet Assigned
`
`Attorney Docket Number |AVN-009DVCN7
`
`
`
`
`
`Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):
`
`CERTIFICATION STATEMENT
`
`That each item of information contained in the information disclosure statement was first cited in any communication
`from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the
`information disclosure statement. See 37 CFR 1.97(e)(1).
`
`OR
`
`That no item of information contained in the information disclosure statement was cited in a communication from a
`
`foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification
`after making reasonable inquiry, no item of information contained in the information disclosure statement was known to
`any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure
`statement. See 37 CFR 1.97(e)(2).
`
`El
`
`See attached certification statement.
`
`The fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
`
`A certification statement is not submitted herewith.
`
`SIGNATURE
`
`A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the
`form of the signature.
`
`This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the
`public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR
`1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed
`application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you
`require to complete this form andlor suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S.
`Patent and Trademark Office, U.S. Department of Commerce, PO. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND
`FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria,
`VA 22313-1450.
`
`EFSWeb2.1.17
`
`ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH.
`
`/JPM/
`
`
` NamelPrint
`Signature
`2017—10—30
`
`
`
`

`

`Receipt date: 10/30/2017
`
`15/789,862 - GAU: 1674
`
`Privacy Act Statement
`
`
`The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the
`attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised
`that:
`(1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited
`is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to
`process and/or examine your submission related to a patent application or patent.
`If you do not furnish the requested
`information, the U.S. Patent and Trademark Office may not be able to process andr'or examine your submission, which may
`result in termination of proceedings or abandonment of the application or expiration of the patent.
`
`The information provided by you in this form will be subject to the following routine uses:
`
`1.
`
`The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act
`(5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the
`Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record 5.
`
`A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a
`court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement
`negotiations.
`
`A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a
`request involving an individual, to whom the record pertains, when the individual has requested assistance from the
`Member with respect to the subject matter of the record.
`
`A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for
`the information in order to perform a contract. Recipients of information shall be required to comply with the
`requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
`
`A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
`may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
`to the Patent Cooperation Treaty.
`
`A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of
`National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
`
`A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or
`his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to
`recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and
`2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this
`purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make
`determinations about individuals.
`
`A record from this system of records may be disclosed, as a routine use, to the public after either publication of
`the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record
`may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in
`an application which became abandoned or in which the proceedings were terminated and which application is
`referenced by either a published application, an application open to public inspections or an issued patent.
`
`A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law
`enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.
`
`
`
`
`
`
`
`EFS Web 2.1.17
`
`ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH.
`
`/JPM/
`
`